Efficiency of gas cooling and accretion at the disc-corona interface

In star-forming galaxies, stellar feedback can have a dual effect on the circumgalactic medium both suppressing and stimulating gas accretion. The trigger of gas accretion can be caused by disc material ejected into the halo in the form of fountain clouds and by its interaction with the surrounding hot corona. Indeed, at the disc-corona interface, the mixing between the cold/metal-rich disc gas (T ~ 10^6 K) can dramatically reduce the cooling time of a portion of the corona and produce its condensation and accretion. We studied the interaction between fountain clouds and corona in different galactic environments through parsec-scale hydrodynamical simulations, including the presence of thermal conduction, a key mechanism that influences gas condensation. Our simulations showed that the coronal gas condensation strongly depends on the galactic environment, in particular it is less efficient for increasing virial temperature/mass of the haloes where galaxies reside and it is fully ineffective for objects with virial masses larger than 10^13 Msun. This result implies that the coronal gas cools down quickly in haloes with low-intermediate virial mass (Mvir <~ 3 x 10^12 Msun) but the ability to cool the corona decreases going from late-type to early-type disc galaxies, potentially leading to the switching off of accretion and the quenching of star formation in massive systems.Comment: 14 pages, 8 figures, accepted for publication in MNRA

The survival of gas clouds in the Circumgalactic Medium of Milky Way-like galaxies

Observational evidence shows that low-redshift galaxies are surrounded by extended haloes of multiphase gas, the so-called 'circumgalactic medium' (CGM). To study the survival of relatively cool gas (T < 10^5 K) in the CGM, we performed a set of hydrodynamical simulations of cold (T = 10^4 K) neutral gas clouds travelling through a hot (T = 2x10^6 K) and low-density (n = 10^-4 cm^-3) coronal medium, typical of Milky Way-like galaxies at large galactocentric distances (~ 50-150 kpc). We explored the effects of different initial values of relative velocity and radius of the clouds. Our simulations were performed on a two-dimensional grid with constant mesh size (2 pc) and they include radiative cooling, photoionization heating and thermal conduction. We found that for large clouds (radii larger than 250 pc) the cool gas survives for very long time (larger than 250 Myr): despite that they are partially destroyed and fragmented into smaller cloudlets during their trajectory, the total mass of cool gas decreases at very low rates. We found that thermal conduction plays a significant role: its effect is to hinder formation of hydrodynamical instabilities at the cloud-corona interface, keeping the cloud compact and therefore more difficult to destroy. The distribution of column densities extracted from our simulations are compatible with those observed for low-temperature ions (e.g. SiII and SiIII) and for high-temperature ions (OVI) once we take into account that OVI covers much more extended regions than the cool gas and, therefore, it is more likely to be detected along a generic line of sight.Comment: 12 pages, 10 figures. Accepted for publication in MNRA

The origin of the high-velocity cloud complex C

High-velocity clouds consist of cold gas that appears to be raining down from the halo to the disc of the Milky Way. Over the past fifty years, two competing scenarios have attributed their origin either to gas accretion from outside the Galaxy or to circulation of gas from the Galactic disc powered by supernova feedback (galactic fountain). Here we show that both mechanisms are simultaneously at work. We use a new galactic fountain model combined with high-resolution hydrodynamical simulations. We focus on the prototypical cloud complex C and show that it was produced by an explosion that occurred in the Cygnus-Outer spiral arm about 150 million years ago. The ejected material has triggered the condensation of a large portion of the circumgalactic medium and caused its subsequent accretion onto the disc. This fountain-driven cooling of the lower Galactic corona provides the low-metallicity gas required by chemical evolution models of the Milky Way's disc.Comment: 6 pages, 4 figures, 1 table; accepted by MNRA

The survival of gas clouds in the circumgalactic medium of Milky Way-like galaxies

Observational evidence shows that low-redshift galaxies are surrounded by extended haloes of multiphase gas, the so-called circumgalactic medium (CGM). To study the survival of relatively cool gas (T < 105 K) in the CGM, we performed a set of hydrodynamical simulations of cold (T = 104 K) neutral gas clouds travelling through a hot (T = 2 × 106 K) and low-density (n = 10−4 cm−3) coronal medium, typical of Milky Way-like galaxies at large galactocentric distances (∼50–150 kpc).We explored the effects of different initial values of relative velocity and radius of the clouds. Our simulations were performed on a two-dimensional grid with constant mesh size (2 pc), and they include radiative cooling, photoionization heating and thermal conduction. We found that for large clouds (radii larger than 250 pc), the cool gas survives for very long time (larger than 250 Myr): despite that they are partially destroyed and fragmented into smaller cloudlets during their trajectory, the total mass of cool gas decreases at very low rates. We found that thermal conduction plays a significant role: its effect is to hinder formation of hydrodynamical instabilities at the cloud–corona interface, keeping the cloud compact and therefore more difficult to destroy. The distribution of column densities extracted from our simulations is compatible with those observed for low-temperature ions (e.g. Si II and Si III) and for high-temperature ions (O VI) once we take into account that OVI covers much more extended regions than the cool gas and, therefore, it is more likely to be detected along a generic line of sight.LA acknowledges financial support from MARCO POLO 2015- 2016. LA is pleased to thank the University of California Santa Cruz for the hospitality during the first phase of this work. JXP acknowledges partial funding by NASA grants HST-GO-13033.06-A and HST-GO-13846.005-A

Testosterone decreases adiponectin levels in female to male transsexuals

Aim: To evaluate the effect of testosterone (T) on adiponectin serum levels in transsexual female patients. Methods: We measured adiponectin, leptin, luteinizing hormone and follicle stimulating hormone, T, estradiol, lipid profile, biochemical parameters and body composition in 16 transsexual female patients at baseline and after 6 months of T treatment (100 mg Testoviron Depot /10 days, i.m.). Results: Adiponectin levels were 16.9 ± 7.3 mg/mL at baseline and 13.5 ± 7.4 mg/mL at month 6 of T treatment (P < 0.05). Leptin and high-density lipoprotein cholesterol decreased significantly, whereas body mass index, waist circumference and lean body mass increased significantly after 6 months of T treatment. No changes in insulin or Homeostasis Model Assessment were detected. Conclusion: T can significantly reduce adiponectin serum levels in transsexual female patients

Black or red phosphorus yields the same blue phosphorus film

After the discovery of graphene, many other 2D materials have been predicted theoretically and successfully prepared. In this context, single-sheet black phosphorus - phosphorene - is emerging as a viable contender in the field of (2D) semiconductors. Phosphorene offers high carrier mobility and an anisotropic structure that gives rise to a modulation of physical and chemical properties. This opens the way to many novel and fascinating applications related to field-effect transistors and optoelectronic devices. In previous studies, a single layer of blue phosphorene intermixed with Au atoms was grown using purified black phosphorus as a precursor. Starting from the observation that phosphorus vapor mainly consists of P clusters, in this work we aimed at obtaining blue phosphorus using much less expensive purified red phosphorus as an evaporant. By means of microscopy, spectroscopy and diffraction experiments, we show that black or red phosphorus deposition on Au(111) substrates yields the same blue phosphorus film

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

BACKGROUND: The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in patients with and without diabetes mellitus (DM) for their pleiotropic beneficial effects. We tested the hypothesis that SGLT2-I have anti-inflammatory effects along with glucose-lowering properties. Therefore, we investigated the link between stress hyperglycemia, inflammatory burden, and infarct size in a cohort of type 2 diabetic patients presenting with AMI treated with SGLT2-I versus other oral anti-diabetic (OAD) agents. METHODS: In this multicenter international observational registry, consecutive diabetic AMI patients undergoing percutaneous coronary intervention (PCI) between 2018 and 2021 were enrolled. Based on the presence of anti-diabetic therapy at the admission, patients were divided into those receiving SGLT2-I (SGLT-I users) versus other OAD agents (non-SGLT2-I users). The following inflammatory markers were evaluated at different time points: white-blood-cell count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-platelet ratio (NPR), and C-reactive protein. Infarct size was assessed by echocardiography and by peak troponin levels. RESULTS: The study population consisted of 583 AMI patients (with or without ST-segment elevation): 98 SGLT2-I users and 485 non-SGLT-I users. Hyperglycemia at admission was less prevalent in the SGLT2-I group. Smaller infarct size was observed in patients treated with SGLT2-I compared to non-SGLT2-I group. On admission and at 24&nbsp;h, inflammatory indices were significantly higher in non-SGLT2-I users compared to SGLT2-I patients, with a significant increase in neutrophil levels at 24&nbsp;h. At multivariable analysis, the use of SGLT2-I was a significant predictor of reduced inflammatory response (OR 0.457, 95% CI 0.275-0.758, p = 0.002), independently of age, admission creatinine values, and admission glycemia. Conversely, peak troponin values and NSTEMI occurrence were independent predictors of a higher inflammatory status. CONCLUSIONS: Type 2 diabetic AMI patients receiving SGLT2-I exhibited significantly reduced inflammatory response and smaller infarct size compared to those receiving other OAD agents, independently of glucose-metabolic control. Our findings are hypothesis generating and provide new insights on the cardioprotective effects of SGLT2-I in the setting of coronary artery disease. TRIAL REGISTRATION: Data are part of the ongoing observational registry: SGLT2-I AMI PROTECT. CLINICALTRIALS: gov Identifier: NCT05261867

Alone on a wide wide sea. The origin of SECCO 1, an isolated star-forming gas cloud in the Virgo cluster

SECCO 1 is an extremely dark, low-mass (M* ≃ 105 M⊙), star-forming stellar system lying in the low-velocity cloud (LVC) substructure of the Virgo cluster of galaxies, and hosting several HII regions. Here, we review our knowledge of this remarkable system, and present the results of (a) additional analysis of our panoramic spectroscopic observations with MUSE, (b) the combined analysis of Hubble Space Telescope and MUSE data, and (c) new narrowband observations obtained with OSIRIS@GTC to search for additional HII regions in the surroundings of the system. We provide new evidence supporting an age as young as ≲4Myr for the stars that are currently ionizing the gas in SECCO 1. We identify only one new promising candidate HII region possibly associated with SECCO 1, thus confirming the extreme isolation of the system.We also identify three additional candidate pressure-supported dark clouds in Virgo among the targets of the SECCO survey. Various possible hypotheses for the nature and origin of SECCO 1 are considered and discussed, also with the help of dedicated hydrodynamical simulations showing that a hydrogen cloud with the characteristics of SECCO 1 can likely survive for ≳1 Gyr while travelling within the LVC Intra Cluster Medium.GB gratefully acknowledges the financial support by the Spanish Ministry of Economy and Competitiveness under the Ramon y Cajal Programme (RYC-2012-11537) and the grant AYA2014-56795-P. FC acknowledges funding from the INAF PRIN-SKA 2017 1.05.01.88.04

Performance of Prognostic Scoring Systems in MINOCA: A Comparison among GRACE, TIMI, HEART, and ACEF Scores

Background: the prognosis of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) is not benign; thus, prompting the need to validate prognostic scoring systems for this population. Aim: to evaluate and compare the prognostic performance of GRACE, TIMI, HEART, and ACEF scores in MINOCA patients. Methods: A total of 250 MINOCA patients from January 2017 to September 2021 were included. For each patient, the four scores at admission were retrospectively calculated. The primary outcome was a composite of all-cause death and acute myocardial infarction (AMI) at 1-year follow-up. The ability to predict 1-year all-cause death was also tested. Results: Overall, the tested scores presented a sub-optimal performance in predicting the composite major adverse event in MINOCA patients, showing an AUC ranging between 0.7 and 0.8. Among them, the GRACE score appeared to be the best in predicting all-cause death, reaching high specificity with low sensitivity. The best cut-off identified for the GRACE score was 171, higher compared to the cut-off of 140 generally applied to identify high-risk patients with obstructive AMI. When the scores were tested for prediction of 1-year all-cause death, the GRACE and the ACEF score showed very good accuracy (AUC = 0.932 and 0.828, respectively). Conclusion: the prognostic scoring tools, validated in AMI cohorts, could be useful even in MINOCA patients, although their performance appeared sub-optimal, prompting the need for risk assessment tools specific to MINOCA patients

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Aims: To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). Methods: In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization. Results: The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p &lt; 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p &lt; 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33–0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21–0.98; p = 0.041). Conclusions: In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI. Registration: Data are part of the observational international registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov Identifier: NCT05261867